ライフサイエンスコーパス: clinical deterioration

1 ictors of waitlist mortality (or removal for clinical deterioration).

2 as in the collection, bacteremia, sepsis, or clinical deterioration).

3 history of 2 weeks of symptom worsening, or clinical deterioration).

4 o identify children experiencing significant clinical deterioration.

5 te a protocol designed to detect evidence of clinical deterioration.

6 y escalation of immunosuppression to prevent clinical deterioration.

7 with appropriate surveillance for unexpected clinical deterioration.

8 illacea did not appear to be associated with clinical deterioration.

9 es and more than 8 hours before the onset of clinical deterioration.

10 formed on admission at 7 days and in case of clinical deterioration.

11 e are merely plausible surrogates for future clinical deterioration.

12 n case of persistent ST-segment elevation or clinical deterioration.

13 thema nodosum leprosum) that result in major clinical deterioration.

14 Services interventions to reduce this early clinical deterioration.

15 er unsuspected CHF in patients with COPD and clinical deterioration.

16 s of age, followed by steady or intermittent clinical deterioration.

17 as hemodynamic aberrancies may cause severe clinical deterioration.

18 at risk for worsening disease in advance of clinical deterioration.

19 to support sepsis detection before patients' clinical deterioration.

20 By 48 hrs, 36 (68%) patients had manifested clinical deterioration.

21 ion with a specific p38 MAPK inhibitor halts clinical deterioration.

22 ncreasing body temperature may be related to clinical deterioration.

23 ; this shift heralds CD4+ cell depletion and clinical deterioration.

24 relationship between insulin deficiency and clinical deterioration.

25 , persistent bacillary load, and progressive clinical deterioration.

26 s never an option because of the rapidity of clinical deterioration.

27 tional imaging in the presence of continuing clinical deterioration.

28 cute problem, and it did not seem to precede clinical deterioration.

29 in the fluvoxamine-treated group experienced clinical deterioration.

30 formed on admission at 7 days and in case of clinical deterioration.

31 oid pathology might be important to halt the clinical deterioration.

32 downstream tau pathology and, consequently, clinical deterioration.

33 inflammation is thought to drive relentless clinical deterioration.

34 of atrophy measures to estimate longitudinal clinical deterioration.

35 penia, hemodilution, and other indicators of clinical deterioration.

36 related Organ Failure Assessment can predict clinical deterioration.

37 ourse characterized by rapid progression and clinical deterioration.

38 t was death on the waitlist or delisting for clinical deterioration.

39 ettings, and they can improve predictions of clinical deterioration.

40 second examination was performed in case of clinical deterioration.

41 can also be useful to estimate longitudinal clinical deterioration.

42 ansplant or removal from the waitlist due to clinical deterioration.

43 ly detection of disease progression prior to clinical deterioration.

44 tify patients based on a new outcome metric, clinical deterioration.

45 assessment skills that nurses used to detect clinical deterioration.

46 ascular events and 2-fold increased risk for clinical deterioration.

47 , consciousness level, and other evidence of clinical deterioration.

48 mild or no symptoms unless there is risk of clinical deterioration.

49 nal critical care resources to patients with clinical deterioration.

50 line in exercise capacity may be a marker of clinical deterioration.

51 of all ages and frequently leads to a rapid clinical deterioration.

52 individuals at the greatest risk of serious clinical deterioration.

53 focused on prespecified measures of nonfatal clinical deterioration.

54 o adverse events, were found at high risk of clinical deterioration.

55 elin is limited, contributing to progressive clinical deterioration.

56 on of patients removed from the waitlist for clinical deterioration.

57 ers, 2206 patients were removed for death or clinical deterioration.

58 Conversely, of true removals for clinical deterioration, 154 of 612 (25.2%) were misclass

59 oved from the waitlist due to death (331) or clinical deterioration (2194) since 2002.

60 The primary outcome was a composite of clinical deterioration (30-day mortality, mechanical ven

61 spiratory syndrome coronavirus 2, leading to clinical deterioration 7 to 10 days after initial presen

62 nd half as likely to be removed for death or clinical deterioration (9.2% vs 18.2%, P = 0.046).

63 Clinical deterioration affected RANO-BM icORR; however,

64 cting a system's ability to detect and treat clinical deterioration after complications.

65 left ventricular dysfunction were at risk of clinical deterioration after digoxin withdrawal despite

66 tprocedure blush reduction are predictors of clinical deterioration after embolization.

67 Of the 12 patients, three experienced acute clinical deterioration after embolization.

68 In-hospital clinical deterioration after presentation including recu

69 dy provides a snapshot of the recognition of clinical deterioration among enrolled and registered nur

70 iomarkers, can reliably estimate the risk of clinical deterioration and 28-day mortality among immuno

71 ) higher rate of death or removal because of clinical deterioration and a 42% (95% CI, 10-85%) higher

72 of pulmonary hypertension is associated with clinical deterioration and a substantially increased mor

73 reases of p-tau217 were also associated with clinical deterioration and brain atrophy in preclinical

74 ogressors), and five were selected for rapid clinical deterioration and CD4 count decline (rapid prog

75 Clinical deterioration and death data were extracted fro

76 and right heart failure have a high risk of clinical deterioration and death during or soon after en

77 one day prior to infection results in rapid clinical deterioration and death of mice within 6 days p

78 drugs, and is among the events that predict clinical deterioration and death.

79 left ventricular function and can result in clinical deterioration and even death.

80 Responders were patients who experienced no clinical deterioration and had improvement or stabilizat

81 in bone marrow-derived cells caused delayed clinical deterioration and hemorrhagic conversion of the

82 tems (PEWS) aid with early identification of clinical deterioration and improve outcomes in children

83 Occurrence of AF in PH indicates clinical deterioration and more advanced disease.

84 Dexamethasone therapy prevented clinical deterioration and reduced the need for blood tr

85 rebral venous sinus thrombosis, 12 (30%) had clinical deterioration and repeat imaging demonstrated e

86 Recurrent clinical deterioration and repeat medical emergency team

87 of patients (n = 337) experienced recurrent clinical deterioration and repeat medical emergency team

88 Patients more likely to experience recurrent clinical deterioration and repeat medical emergency team

89 ts in COVID-19-infected patients, preventing clinical deterioration and the need for hospitalization.

90 e the role of enrolled nurses in recognizing clinical deterioration and to provide a big picture of h

91 ores have been developed to detect inpatient clinical deterioration and trigger rapid response activa

92 There were significantly fewer episodes of clinical deterioration and/or bailout (1.8% versus 5.4%;

93 LBMT had lower rates of clinical deterioration and/or bailout and postprocedural

94 acranial hemorrhage, (3) major bleeding, (4) clinical deterioration and/or escalation to bailout, and

95 pse, relapse or study discontinuation due to clinical deterioration, and acute exacerbation.

96 s of transplantation, delisting due to death/clinical deterioration, and all-cause survival from the

97 19 before the appearance of obvious signs of clinical deterioration, and it can be used as a tool to

98 t to an alternate thrombus removal strategy, clinical deterioration, and major bleeding.

99 nsitivity, diarrhea and vomiting, skin rash, clinical deterioration, and patient's wishes in one pati

100 Limited data on clinical improvement, clinical deterioration, and serious adverse events showe

101 2 (SARS-CoV-2) RNAemia and disease severity, clinical deterioration, and specific EPCs.

102 ified fluvoxamine as effective in preventing clinical deterioration, and subgrouping analysis suggest

103 education for bedside clinicians in signs of clinical deterioration, and we also suggest that patient

104 ory of 2 weeks of clinical deterioration, or clinical deterioration as judged by the clinician.

105 strated improvement or stabilization without clinical deterioration, as compared with 65 of 146 in th

106 of symptomatic improvement and lower risk of clinical deterioration, as evaluated by changes in the N

107 ata, consistently indicated a higher risk of clinical deterioration associated with an advanced AD sc

108 In patients presenting with clinical deterioration at follow-up, acute RV dysfunctio

109 HT and higher rate of delisting for death or clinical deterioration at the highest urgent status, whi

110 Real-time clinical deterioration automated alert and trigger syste

111 riences facilitated the early recognition of clinical deterioration before the patient turned haemody

112 s can outperform older methods in predicting clinical deterioration, but rigorous prospective data on

113 alert clinicians to patients at high risk of clinical deterioration, but there is limited evidence fo

114 Fluvoxamine may prevent clinical deterioration by stimulating the sigma-1 recept

115 ear the most striking finding was that while clinical deterioration continued in the placebo-treated

116 IM) versus virus persistence and progressive clinical deterioration (CVB3-PERS).

117 Clinical deterioration, defined as a transfer from ward

118 failure by day 8 after enrolment, defined as clinical deterioration, development of a serious adverse

119 failure by day 8 after enrolment, defined as clinical deterioration, development of a serious adverse

120 Of the 122 enrolled, four were excluded (clinical deterioration, diagnosis of cystic fibrosis, pr

121 The adjusted risk of death or delisting for clinical deterioration did not significantly differ betw

122 Among 9 patients who experienced clinical deterioration during follow-up, 8 had positive

123 Among nine patients who experienced clinical deterioration during follow-up, eight had posit

124 were associated with a greater reduction in clinical deterioration event mortality after PEWS implem

125 le analyses assessed the correlation between clinical deterioration event mortality and centre charac

126 ence rate ratios (IRRs) were used to compare clinical deterioration event mortality before and after

127 S implementation was associated with reduced clinical deterioration event mortality in paediatric pat

128 e analysis of centre characteristics, higher clinical deterioration event mortality rates before PEWS

129 Overall clinical deterioration event mortality was 32.9%.

130 The primary outcome was clinical deterioration event mortality.

131 vel (IRR 0.86 [95% CI 0.68-1.09]; p=0.22) or clinical deterioration event rates before PEWS implement

132 The mortality rate due to a clinical deterioration event was 1.33 events per 1000 pa

133 [55.3%] female), 16 693 (4.6%) experienced a clinical deterioration event.

134 017, and May 31, 2021, prospectively tracked clinical deterioration events and monthly inpatient-days

135 Proyecto EVAT; these centres documented 2020 clinical deterioration events in 1651 patients over 556

136 ms (PEWS) aid in the early identification of clinical deterioration events in children admitted to ho

137 The median age of patients with clinical deterioration events was 8.5 years (IQR 3.9-13.

138 ars (IQR 3.9-13.2), and 1095 (54.2%) of 2020 clinical deterioration events were reported in male pati

139 cords and were classified into 7 categories: clinical deterioration, financial access, clinician-dire

140 replacement therapy, and time to in-hospital clinical deterioration following admission.

141 le to identify patients at risk of recurrent clinical deterioration following medical emergency team

142 of 3,200 patients with and without recurrent clinical deterioration following medical emergency team

143 port vector machines for predicting imminent clinical deterioration for patients based on cross-secti

144 se in probability that a patient will have a clinical deterioration from sepsis within 24 h.

145 for survival or waitlist removal because of clinical deterioration from the time of heart transplant

146 at our institution after rapidly progressive clinical deterioration from this infection, with necroti

147 Early identification of patients at risk for clinical deterioration has relied on manually calculated

148 es after an automated detection of impending clinical deterioration have not been widely reported.

149 competing risks analysis, remdesivir reduced clinical deterioration (hazard ratio [HR], 0.73; 95% con

150 lower risk of waitlist removal for death or clinical deterioration (hazard ratio, 0.57 [95% CI, 0.45

151 g was independently associated with an early clinical deterioration (hazard ratio, 2.77 [95% CI, 1.47

152 ity of heart failure and reduces the risk of clinical deterioration, hospitalization, and other serio

153 d neurofilament light (NfL) together predict clinical deterioration in 435 CU individuals followed fo

154 We present an example of severe clinical deterioration in a patient with HCM due to supe

155 if frontline nurses can recognize and act on clinical deterioration in a timely manner.

156 hine and opioid use were not associated with clinical deterioration in acute pancreatitis.

157 f impedance cardiography (ICG) in predicting clinical deterioration in ambulatory patients with heart

158 d whether early morphine use correlates with clinical deterioration in AP.

159 D atrophy scores were associated with faster clinical deterioration in bvFTD (1.86-point change in Cl

160 tablishment of chronic infection and ensuing clinical deterioration in CF.

161 t of PEWS implementation on mortality due to clinical deterioration in children with cancer in 32 res

162 a novel therapeutic opportunity to attenuate clinical deterioration in COVID-19 and improve resilienc

163 g this process, reduced ACE2 could result in clinical deterioration in COVID-19 patients with diabete

164 he risk of virus persistence and progressive clinical deterioration in CVB3 cardiomyopathy.

165 how enrolled and registered nurses recognize clinical deterioration in general ward patients.

166 d to improve the recognition and response to clinical deterioration in hospital wards.

167 Clinical deterioration in human immunodeficiency virus t

168 Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's

169 , in the form of LTP, is crucial to contrast clinical deterioration in MS.

170 odulatory therapy, resulting in irreversible clinical deterioration in patients with MMP.

171 onsidered in the differential diagnosis of a clinical deterioration in posttransplant patients treate

172 own about the effect of drugs on the risk of clinical deterioration in surviving patients.

173 y warning decision support tools to identify clinical deterioration in the hospital are widely used,

174 Failure to detect clinical deterioration in the hospital is common and ass

175 We looked at evidence of clinical deterioration in the Metoprolol CR/XL Randomize

176 This suggests that clinical deterioration in these patients may occur by a

177 Clinical deterioration in this study is measured by in-h

178 ing therapeutic anticoagulation (a proxy for clinical deterioration, including thromboembolic events)

179 The introduction of a two-tier response to clinical deterioration increased ICU admissions triggere

180 me of early treatment failure defined as [1] clinical deterioration indicated by development of shock

181 The primary outcome was clinical deterioration (intensive care unit admission, i

182 Inpatient clinical deterioration is associated with substantial mo

183 tification of patients at high likelihood of clinical deterioration is important for guiding decision

184 -hippocampal markers to predict the earliest clinical deterioration is less clear.

185 coccal meningitis (CM) frequently experience clinical deterioration, known as cryptococcosis-associat

186 infections may be accompanied by (transient) clinical deterioration, known as paradoxical reaction.

187 Transient clinical deteriorations, known as paradoxical reactions

188 disease process characterized by progressive clinical deterioration leading rapidly to cardiac death

189 cused on registered nurses as recognizers of clinical deterioration, little research has sought to ex

190 Clinical deterioration may be mitigated by appropriate p

191 ngth of hospital stay, clinical improvement, clinical deterioration, mechanical ventilation use, and

192 ovement (moving to less advanced stage), and clinical deterioration (moving to more advanced stage) w

193 scalated, mainly to carbapenems, usually for clinical deterioration (n = 480; 65.9%).

194 adverse events within 7 days (a composite of clinical deterioration necessitating rescue therapy, PE-

195 ed at 20 hours and at discharge and included clinical deterioration, need for craniotomy, and death.

196 In patients with PH and AF, parameters of clinical deterioration (NYHA/WHO functional class, 6-min

197 Clinical deterioration occurred in 0 of 80 patients in t

198 Clinical deterioration occurred in 20% of patients.

199 Clinical deterioration occurred in 49.1% (morphine) vs.

200 a step-wise fashion up to 30 cm H2O or until clinical deterioration occurred.

201 als of care discussions with patients before clinical deterioration occurs.

202 hich mepolizumab administration reversed the clinical deterioration of asthma, which was possibly cau

203 ant parameter in the simulation of long-term clinical deterioration of bond integrity.

204 The repurposing of drugs to prevent clinical deterioration of COVID-19 patients was trialed

205 reduced CASP4 expression leads to the potent clinical deterioration of glioma patients.

206 HF) device diagnostic information to predict clinical deterioration of HF in patients with systolic l

207 Clinical deterioration of patients hospitalized outside

208 however, and that it may play a role in the clinical deterioration of patients with congestive heart

209 Is late clinical deterioration often or invariably tied to the i

210 Postoperative clinical deterioration on inpatient hospital services is

211 curacy of different techniques for detecting clinical deterioration on the wards in a large, multicen

212 E nor PERSEVERE-II performed well to predict clinical deterioration or 28-day mortality, thus we deri

213 dels indicate common physiologic pathways to clinical deterioration or death from bacterial infection

214 ion or GGO on chest CT independently predict clinical deterioration or death in patients with COVID-1

215 ars, 78 men), of whom 39 (32.5%) experienced clinical deterioration or death.

216 on Rating Scale with a history of 2 weeks of clinical deterioration, or clinical deterioration as jud

217 ed iloprost, due to lower airway reactivity, clinical deterioration, or death.

218 iting for ReTx with fewer removed for death, clinical deterioration, or improvement.

219 ared with placebo, had a lower likelihood of clinical deterioration over 15 days.

220 e valuable information regarding the risk of clinical deterioration over 18 months among patients wit

221 waitlist time, waitlist removal for death or clinical deterioration, posttransplant survival, and sur

222 of patients who died, and an apparent acute clinical deterioration preceded death in 47% of these pa

223 c data are critical for early recognition of clinical deterioration, prognostication, and guiding tre

224 Regardless of the etiology, rapid clinical deterioration, prolonged stay in intensive care

225 ression of cutaneous disease, accompanied by clinical deterioration, pulmonary failure, and death.

226 No device-related clinical deterioration, pulmonary vascular injury, or ca

227 diagnosis of 4-repeat (4R) tauopathy and the clinical deterioration rate (assessed by longitudinal me

228 eart failure is characterized by progressive clinical deterioration reflected in frequent hospital ad

229 e 68 listed patients in whom the rapidity of clinical deterioration, reflected in increasing APACHE I

230 lan-Meier curves were reported for response, clinical deterioration, relapse and relapse-free surviva

231 ated with older age and renal involvement; a clinical deterioration/relapse was associated with high

232 rt failure outpatients at increased risk for clinical deterioration remains a critical challenge, wit

233 y identification of patients at high risk of clinical deterioration represents one of the greatest ch

234 Once stability was achieved, clinical deterioration requiring intensive care, coronar

235 Clinical deteriorations result in increases to the LAS;

236 Further work-up after clinical deterioration revealed an increase in the lesio

237 ement in necrotizing pancreatitis is common; clinical deterioration should prompt its evaluation.

238 Clinical deterioration, side effects, and poor complianc

239 e learning methods more accurately predicted clinical deterioration than logistic regression.

240 tion establishes an electronic descriptor of clinical deterioration that is strongly associated with

241 ion but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up.

242 more likely than patients without recurrent clinical deterioration to be subsequently admitted to IC

243 Secondary outcomes included clinical deterioration (transfer to ICU, initiation of v

244 every 2 weeks until disease progression and clinical deterioration, unacceptable toxicity, or other

245 After clinical deterioration using meropenem monotherapy, trea

246 the rate of HT waitlist removal for death or clinical deterioration was assessed using multivariable

247 A model to predict clinical deterioration was developed rapidly in response

248 Clinical deterioration was seen in 15% of subjects.

249 analysis where waitlist removal for death or clinical deterioration was the competing event.

250 ousand three hundred forty-three episodes of clinical deterioration were identified with a rise in Se

251 truly removed from the waitlist for death or clinical deterioration were misclassified as "other." Th

252 Patients with recurrent clinical deterioration were more likely than patients wi

253 physiologic signatures may be present before clinical deterioration, when treatment might be more eff

254 ntify hospitalized patients at high risk for clinical deterioration (which permits automated, real-ti

255 received placebo and those without confirmed clinical deterioration while receiving IVIG could enter

256 The primary outcome was clinical deterioration within 15 days of randomization d

257 f cumulative treatment failure at day 14 was clinical deterioration within 48 hours of enrollment (33

258 The primary analysis assessed clinical deterioration within 72 hours of evaluation for

259 of available evidence points to a meaningful clinical deterioration within a few weeks following the

260 ent cohort to predict a composite outcome of clinical deterioration within the first five days of hos

261 variables, and found that memantine reduced clinical deterioration without significant adverse effec

262 55 patients exhibited clinical deterioration, yielding an annual progression r